Printer Friendly

Stem Cells files IND with FDA for transplanting human neural brain stem cells.

StemCells, Inc., Palo Alto, CA, announced it has filed its first Investigational New Drug (IND) application to the FDA for approval to begin its first clinical investigation of its human neural stem cells (HuCNS-SC-StemCells proprietary neural cell therapy product) in the treatment of Batten disease.

Batten disease is a rare, fatal genetic disorder that affects the central nervous system of children. If approved, the company says it will be the first-ever FDA-approved clinical trial to use a purified composition of human neural stem cells as the potential therapeutic agent.

StemCells says if it receives FDA approval, the study will be conducted at Lucile Packard Children's Hospital/Stanford University Medical Center. The proposed Phase I trial is designed to investigate the safety of HuCNS-SC in the treatment of infantile and late-infantile neuronal ceroid lipofuscinosis (NCL), the most severe forms of a group of disorders commonly referred to as Batten disease. The primary objective will be to measure the safety of HuCNS-SC and evaluate HuCNS-SC's ability to affect the progression of the disease.

Contact: Judi Lum - (615) 475-3100, Web site: www.stemcellsinc.com
COPYRIGHT 2005 Transplant Communications, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:nvestigational New Drug
Publication:Transplant News
Article Type:Brief Article
Geographic Code:1USA
Date:Jan 15, 2005
Words:181
Previous Article:DOR BioPharma reports orBec improves mortality rates in leukemia patients following bone marrow transplant.
Next Article:Panel recommends UC medical schools use barcodes, video cameras to thwart willed body program abuses.
Topics:


Related Articles
New sources and uses for stem cells.
Italian scientists find "switch" that turns stem cells into neurons.
Incara announces issuance of additional patent for isolating liver progenitor cells.
Incara to file IND with FDA for human clincal trials of liver stem cell program.
StemCells gets FDA ok to begin phase I clinical trial to transplant neural stem cells to treat Batten disease.
Neuralstem's cells restore motor function in spinal ischemia-paralyzed rats.
Ruling in favor of Neuralstem leads to stay of Stemcells lawsuit.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters